The Phase 2 trial of retatrutide (Jastreboff et al., New England Journal of Medicine , 2023) reported that the most common adverse effects were gastrointestinal in nature (nausea, vomiting, diarrhoea), consistent with the GLP-1 receptor agonist class
doi: 10.1038/s41556-024-01425-8
Mitochondrial dysfunction and its relationship with mTOR signaling and oxidative damage in autism spectrum disorders
Zhu Y, Jameson E, Crosatti M, et al
Mobile service is available for at-home recovery when you need it most
I had tried diet pills in the past, but nothing really worked long term. However, within a month of starting Semaglutide, John noticed a significant reduction in his appetite